|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
0
|
36
|
January 21, 2025
|
|
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific Acceptable Intakes-Pub
|
|
10
|
606
|
January 20, 2025
|
|
Acceptable Intake N-Nitrosobiotin (N-Nitrosamide)
|
|
2
|
173
|
January 13, 2025
|
|
SCIEX Webinar: Unlocking precision: nitrosamine and NDSRI analysis(16.1.2025 10:30 CET)
|
|
0
|
232
|
January 12, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
17
|
3716
|
January 10, 2025
|
|
The quagmire with the interim limit of nitroso duloxetine
|
|
0
|
228
|
January 6, 2025
|
|
FDA Updates Recall on Blood Pressure Medication Due to Possible Carcinogen
|
|
3
|
733
|
December 27, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
7
|
1056
|
December 18, 2024
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
6
|
953
|
December 16, 2024
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
12
|
2306
|
December 13, 2024
|
|
Limit of N-nitroso morpholine in Rocuronium Br
|
|
0
|
71
|
December 12, 2024
|
|
Autonomous CPCA Web-based calculator FREE
|
|
31
|
5368
|
December 12, 2024
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
35
|
2892
|
December 3, 2024
|
|
N-Nitroso Sertraline
|
|
7
|
344
|
November 27, 2024
|
|
🛑 N-nitroso Ticagrelor
|
|
12
|
2835
|
October 25, 2024
|
|
N-Nitroso Metoprolol
|
|
0
|
110
|
November 20, 2024
|
|
Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure -Pub
|
|
19
|
1639
|
November 6, 2024
|
|
⁉️ Duloxetine Impurity NDSRI
|
|
7
|
652
|
November 1, 2024
|
|
Hypothetical Nitrosamine in 1-H Indazole / CPCA Approach
|
|
3
|
122
|
October 31, 2024
|
|
📅 Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis
|
|
3
|
503
|
October 30, 2024
|
|
What is CPCA Score for “N-nitroso of 3-Amino-1,2,4-triazole"
|
|
5
|
227
|
October 30, 2024
|
|
N-Nitroso Desmethyl Tramadol
|
|
3
|
313
|
October 29, 2024
|
|
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA) -Pub
|
|
0
|
156
|
October 29, 2024
|
|
Hexamethyldisilazane (HMDS) can form Nitrosamine Impurity?
|
|
7
|
502
|
October 29, 2024
|
|
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da -Pub
|
|
0
|
214
|
October 28, 2024
|
|
Software for prediction of NDSRI generation
|
|
5
|
526
|
October 24, 2024
|
|
N-Nitroso duloxetine methods from SwissMedic and Taiwan FDA
|
|
0
|
121
|
October 24, 2024
|
|
Nationwide recall of duloxetine
|
|
0
|
233
|
October 23, 2024
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
16
|
482
|
October 21, 2024
|
|
Dynamics of Nitroso-STG-19 entering the blood circulation
|
|
1
|
121
|
October 10, 2024
|